Thetis Pharmaceuticals reports that Dr. Chris Takimoto has joined its Scientific Advisory Board.
Dr. Takimoto joins the Thetis SAB with 30 years of experience in cancer research and development. He currently is the Chief Medical Officer of IGM Biosciences and previously served as Senior Vice President, Oncology for Gilead Sciences following Gilead’s acquisition of Forty Seven, the biotechnology company that developed Magrolimab, where he served as Chief Medical Officer.